The Office of the Vice President for Research (OVPR) would like to share the following opportunity with faculty and students interested in pursuing SBIR funding from NIH.
The National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases (NIAID) are coming to JLABS @ NYC! On September 14, program directors Todd Haim with NCI, Natalia Kruchinin and Mike Minnicozzi with NIAID, will be presenting funding opportunities and other resources for startups in cancer technology and in allergy, immunology and infectious diseases.
You will learn about 15 new targeted funding opportunities in cancer detection, diagnosis, and treatment in high priority areas of research for the NCI. Although the trends reflect improvements in cancer treatments, and advances in technology have led to better tools for understanding, detecting, and diagnosing cancer – we still have work to do. In 2017, an estimated 1,688,780 new cases of cancer will be diagnosed in the United States. The NCI is poised to reduce the burden of cancer in this country and around the world at an accelerated pace.
Additionally, high priority research areas of interest for NIAID investigator-initiated research as well as targeted opportunities will be discussed. NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic and allergic diseases. NIAID has a unique mandate requiring the Institute to respond to emerging public health threats within the US and abroad. Its research portfolio includes a diverse selection across research in three key mission areas: 1) HIV/AIDS, 2) Allergy, Immunology and Transplantation, and 3) Microbiology and Infectious Diseases.
For more information and to register, visit https://investorspotlight-blastshare.eventbrite.com
For more information, contact: Office of the Vice President for Research at ovpr@uconn.edu